---
title: "CICC Remains a Buy on Yonghe Medical Group Co., Ltd. (2279)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/281703443.md"
description: "In a report released yesterday, from CICC maintained a Buy rating on Yonghe Medical Group Co., Ltd., with a price target of HK$2.46.End of Quarter Sale - 50% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Yonghe Medical Group Co., Ltd. has an analyst consensus of Moderate Buy, with a price target consensus of HK$2.46."
datetime: "2026-04-05T05:15:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281703443.md)
  - [en](https://longbridge.com/en/news/281703443.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281703443.md)
---

# CICC Remains a Buy on Yonghe Medical Group Co., Ltd. (2279)

In a report released yesterday, from CICC maintained a Buy rating on Yonghe Medical Group Co., Ltd., with a price target of HK$2.46.

### End of Quarter Sale - 50% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Yonghe Medical Group Co., Ltd. has an analyst consensus of Moderate Buy, with a price target consensus of HK$2.46.

### Related Stocks

- [02279.HK](https://longbridge.com/en/quote/02279.HK.md)
- [516610.CN](https://longbridge.com/en/quote/516610.CN.md)

## Related News & Research

- [Ingenia Communities Group (INA) Gets a Buy from UBS](https://longbridge.com/en/news/290394444.md)
- [Desjardins Reaffirms Their Buy Rating on Empire Co Cl A NV (EMP.A)](https://longbridge.com/en/news/290381097.md)
- [RBC Capital Sticks to Their Buy Rating for Firstgroup (FGP)](https://longbridge.com/en/news/290402153.md)
- [Centuria Capital Group (CNI) Receives a Buy from Morgan Stanley](https://longbridge.com/en/news/290394430.md)
- [HKR Maintained at Buy as Analyst Keeps HKD1.63 Target Price, Citing Deep NAV Discount and Multi‑Year Profit Recovery](https://longbridge.com/en/news/290401703.md)